Pauline Funchain's Avatar

Pauline Funchain

@funchainmd.bsky.social

Melanoma oncology @Stanford. Study hereditary genetics and irAEs. LA explant in SF via Ohio State, NIH/NHGRI, Harbor UCLA, and Cleveland Clinic. Sports fan, geek and mom. APD Hem/Onc fellowship. ASPirE founder, Checkpoint Now. COI http://bit.ly/43UCDOz

3,961 Followers  |  1,016 Following  |  225 Posts  |  Joined: 09.11.2024  |  1.8747

Latest posts by funchainmd.bsky.social on Bluesky

Video thumbnail

@mcuban.bsky.social recently brought his business expertise to #StanDOM's Grand Rounds β€” diagnosing the American healthcare system & proposing a treatment plan.

Watch the full video & read the key takeaways: stanford.io/3FbkfZr

12.06.2025 21:05 β€” πŸ‘ 3    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0

This program reflects our commitment to fostering meaningful partnerships and supporting the next generation of leaders in cancer research. We’re proud to be part of their journey and look forward to the ideas and energy they bring to our community this summer. @funchainmd.bsky.social

11.06.2025 21:06 β€” πŸ‘ 4    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0

Wrapping up #ASCO24 with this thought: let’s get more people under the survival curve and lift it up - it might be prolonged survival, it might even be cure. Every moment counts.

May we all walk into our post ASCO lives inspired ✨ πŸ“ˆ @ascocancer.bsky.social @aspire-cop.bsky.social

04.06.2025 19:11 β€” πŸ‘ 2    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0

Melanoma orals #9 ➑️ DANTE trial in 1L metastatic melanoma comparing 1 vs 2 yr anti PD1 + anti CTLA4

➑️ obstacles to accrual, underpowered, stopping at 1 year non inferior*
➑️ no difference in QOL but less concern with staying on treatment

Sarah Danson U Sheffield #ASCO25 @ascocancer.bsky.social

03.06.2025 17:25 β€” πŸ‘ 2    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image Post image Post image Post image

Melanoma orals #8 ➑️ S2000 enco bini nivo vs ipi nivo in symptomatic melanoma brain mets

➑️First randomized trial in symptomatic brain mets
➑️Significant PFS improvement with triple therapy over ipi nivo
➑️No significant OS benefit

Zeynep Eroglu, Moffitt #ASCO25 @ascocancer.bsky.social

03.06.2025 17:11 β€” πŸ‘ 3    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Post image Post image Post image Post image

Melanoma orals #7 ➑️ 5 year overall survival from DREAMSEQ

➑️ 63.3% for ipi/nivo first
➑️ 33.9% for dab/tram first

Mike Atkins, Georgetown #ASCO25 @ascocancer.bsky.social

03.06.2025 17:03 β€” πŸ‘ 3    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image Post image Post image Post image

Melanoma orals #7 ➑️ 5 year overall survival from DREAMSEQ

➑️ 63.3% for ipi/nivo first
➑️ 33.9% for dab/tram first

Mike Atkins, Georgetown #ASCO25 @ascocancer.bsky.social

03.06.2025 17:02 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image Post image Post image Post image

Melanoma orals #6 ➑️ ECOG 6194 ph II pembro + injectable TLR9 agonist vidutolimod in stage III melanoma

pCR 71% MPR 79% 1 yr EFS 89%

Me: pCR much higher than other studies but with an injectable agent very hard to interpret the systemic effect

Ahmad Tarhini #ASCO25 @ascocancer.bsky.social

03.06.2025 16:30 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image Post image Post image Post image

Melanoma orals #4 ➑️ ph
II neoadjuvant dostarlimab + anti TIM3 cobolimab in stage III melanoma

D+C with mPR 51.9% with 1 yr EFS 92%

Megan Mooradian @mgbresearch.bsky.social #ASCO25 @ascocancer.bsky.social

03.06.2025 16:18 β€” πŸ‘ 2    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image Post image Post image Post image

Melanoma orals #4 ➑️ ph II neadjuvant anti TIGIT tiragolimab and atezolizumab in stage III melanoma
➑️47.7% pCR
➑️91.7% 12 m RFS for those with MPR
➑️no type 1 DM, AI

Tina Heiken @mayocliniccancer.bsky.social
#ASCO25 @ascocancer.bsky.social
@aspire-cop.bsky.social

03.06.2025 16:00 β€” πŸ‘ 2    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image

Caroline Robert asks if we should move away from CTCAE grading of irAE in trials and acknowledge the AI (which she notes is more likely focal hypopit rather than AI) is actually a 6% rate of permanent medication-requiring disease #irAE #ASCO25 #melsm @ascocancer.bsky.social @aspire-cop.bsky.social

03.06.2025 15:46 β€” πŸ‘ 2    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image Post image

Discussion of 1st set of melanoma orals by Ana Arance - Toxicities are the *key* challenge in the adjuvant setting and mitigation of #irAE are the priority in this setting #ASCO25

@ascocancer.bsky.social @aspire-cop.bsky.social

03.06.2025 15:32 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image Post image Post image Post image

Melanoma orals #3 ➑️ neoadjuvant pembro on stage II/III melanoma

Stage IIC SLN positivity significantly different from historical controls; 2 yr RFS β€œhigh”

Me: Intriguing but hard to understand if true impact given a (moving) historical control

Georgios Karakousis
#ASCO25 @ascocancer.bsky.social

03.06.2025 15:27 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image Post image Post image Post image

Melanoma oral #2 #ASCO25

Ph III adjuvant enco bini - Alex van Akkooi summarizes as a tolerable regimen

@ascocancer.bsky.social

03.06.2025 15:19 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image Post image Post image Post image

Melanoma oral #1 #ASCO25 ➑️ ph III adj rela nivo vs nivo (RELATIVITY 098) - no difference in RFS, DMFS

Presented by Georgina Long @melanomaau.bsky.social @ascocancer.bsky.social

03.06.2025 15:02 β€” πŸ‘ 2    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image

Actually, yes, this and a fantastic set of encyclopedias

02.06.2025 23:19 β€” πŸ‘ 23505    πŸ” 2570    πŸ’¬ 731    πŸ“Œ 273

Seeing this picture gave me joy - thank you for being a light in our community! πŸ’™

03.06.2025 14:23 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image

Amazing to meet my fellow ✨Featured Voice✨ Dr @funchainmd.bsky.social at the #WLO event. Best on your presentation today! β€ͺ@aspire-cop.bsky.social‬ #ASPIRE #ASCO25 #HeForShe πŸ’ž #SuppOncSelfiesπŸ“Έ
@kmittalmd.bsky.social
@ascocancer.bsky.social
@oncodaily.bsky.social

03.06.2025 10:50 β€” πŸ‘ 6    πŸ” 1    πŸ’¬ 1    πŸ“Œ 0
Post image Post image Post image Post image

Where are TIL today, one year later? #ASCO25

➑️4 year OS 22.2%
➑️front line with excellent ORR, although 12 month survival lower than checkpoint inhibition
➑️in real practice, multiple paths to, off, and after TIL for individual patients

Don Lawrence @mgbresearch.bsky.social @ascocancer.bsky.social

03.06.2025 13:56 β€” πŸ‘ 4    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image Post image Post image Post image

Multiple new agents with mechanisms other than immunotherapies under investigation for metastatic melanoma:
➑️ new BRAF targeting agents
➑️ PRMT5 inhibition
➑️ ROR2 ADC
-Meredith McKean, Sarah Cannon
#ASCO25 @ascocancer.bsky.social

03.06.2025 13:35 β€” πŸ‘ 3    πŸ” 2    πŸ’¬ 0    πŸ“Œ 0
Post image Post image Post image Post image

AI imaging of skin cancer has good prediction but predictive power dropped in a larger pretesting dataset - important to check AI algorithms at multiple time points!

Susan Swetter @stanford-cancer.bsky.social #ASCO25 @ascocancer.bsky.social

03.06.2025 13:18 β€” πŸ‘ 4    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image

JAMA Oncology is now on @bsky.app !!

Follow @jamaoncology.bsky.social & @jama.com for oncology content #MedSky #OncSky #ASCO25

02.06.2025 18:09 β€” πŸ‘ 179    πŸ” 52    πŸ’¬ 5    πŸ“Œ 0
Post image Post image Post image

Much less clarity on whether or not to continue systemic immunotherapy after pCR following neoadjuvant therapy

The people have spoken, and they are undedecided - more work to do! #melsm #ASCO25

02.06.2025 19:07 β€” πŸ‘ 4    πŸ” 2    πŸ’¬ 0    πŸ“Œ 0
Post image Post image Post image Post image

Ever wonder how pathologists calculate neoadjuvant response metrics (% residual viable tumor, % necrosis, % regression)? Formulas and recommendations for standardized reporting πŸ‘‡
Janis Taube @hopkinsmedicine.bsky.social #ASCO25 #melsm @ascocancer.bsky.social

02.06.2025 18:54 β€” πŸ‘ 3    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image Post image Post image

Neoadj ipi/nivo is clear winner in melanoma, prompting Genevieve Boland and Diwakar Davar to discuss the CONSTANT communication required between med onc/ surg onc (and relevant subspecialists) perioperatively to address ir-AI or colitis #ASCO25 #irAE @ascocancer.bsky.social @aspire-cop.bsky.social

02.06.2025 18:44 β€” πŸ‘ 4    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Post image Post image Post image Post image

Melanoma rapid oral #9 ➑️ OBX-115, engineered TIL with membrane bound IL15 regulated with acetazolamide

-for 6pt receiving RP2D, 67% ORR, 1 CR, 100% DCR
-mDOR not reached

Jason Chesney U Louisville and @drbetofmdphd.bsky.social @stanford-cancer.bsky.social

#ASCO25 @ascocancer.bsky.social

02.06.2025 16:19 β€” πŸ‘ 7    πŸ” 4    πŸ’¬ 0    πŸ“Œ 0
Post image Post image Post image Post image

Melanoma rapid oral #8 ➑️ TIL product characteristics (cell types) that may predict outcome

Me: Would be great to access a profile that saves patients from high toxicity profile but honestly would be hard to lose options

Lilit Karapetyan @moffittnews.bsky.social #ASCO25 @ascocancer.bsky.social

02.06.2025 16:09 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image Post image Post image Post image

Rapid melanoma oral #7 ➑️ 5 year outcomes with lifileucel
-mDOR 36.5m
-31.3% of responders with sustained response
-3 pts with PR that deepened after about a year
-AEs within first 3 m and drop off dramatically
Theresa Medina U Colo
#ASCO25 @ascocancer.bsky.social

02.06.2025 16:03 β€” πŸ‘ 3    πŸ” 2    πŸ’¬ 0    πŸ“Œ 0
Post image Post image Post image Post image

Melanoma rapid oral #6 ➑️ neoadj lenvatinib + pembro in Merkel cell
-57.7% pCR
-50% at least 1 TRAE

Thoughts - what are we gaining and at what cost? Will be interesting to see long term outcomes given MCC with higher rate of recurrence after CR from IO in stage IV
#ASCO25 @ascocancer.bsky.social

02.06.2025 15:51 β€” πŸ‘ 2    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image Post image Post image Post image

Melanoma rapid orals #5 ➑️ single dose of neoadj ipi 3 + nivo 1 with 59% major pathological response and 9% grade 3+ TRAE. CD8 PET not predictive.
Sarah Lochrin @mskcc.bsky.social
#ASCO25 @ascocancer.bsky.social @aspire-cop.bsky.social

02.06.2025 15:42 β€” πŸ‘ 1    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0

@funchainmd is following 20 prominent accounts